Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug

Bio-Thera Adjusts BAT3306 Clinical Study to Meet Regulatory Standards

Fineline Cube Aug 21, 2025

On August 21, 2025, China-based Bio-Thera Solutions, Ltd. (SHA: 688177) announced a strategic adjustment to...

Company Drug

Novartis’ Atrasentan Approved in China for IgAN Proteinuria Reduction

Fineline Cube Aug 21, 2025

Switzerland-based Novartis (NYSE: NVS) has received approval from China’s National Medical Products Administration (NMPA) for...

Company Drug

Suzhou Zelgen’s ZG005 and Gecacitinib Win NMPA Approval for Advanced Solid Tumors

Fineline Cube Aug 21, 2025

On August 21, 2025, Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266), a China-based company, announced...

Others

Minova’s MI078 Shows Promising Results in Postpartum Depression Trial

Fineline Cube Aug 21, 2025

Nanjing-based Minova Pharmaceuticals Co., Ltd. has announced positive results from a Phase 2 clinical trial...

Company Deals

Abbisko’s ABSK043 Gains IND Approval for KRAS G12C NSCLC in Partnership with Allist

Fineline Cube Aug 21, 2025

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that the Center for Drug Evaluation...

Company Drug

Sino Biopharma’s Zongertinib Receives Second Breakthrough Designation for NSCLC

Fineline Cube Aug 21, 2025

On August 20, 2025, Sino Biopharmaceutical Limited (HKG: 1177) announced that its selective HER2 tyrosine...

Company Deals Medical Device

Haohai Biotech Terminates OK Lens Distribution Deal with Brighten Optix Amid Carl Zeiss Acquisition

Fineline Cube Aug 21, 2025

Shanghai Haohai Biological Technology Co., Ltd. (HKG: 6826, SHA: 688366) announced the termination of its...

Company Deals

Nanjing Zenshine Pharma Partners with Cigalah Medpharm to Advance Sebaloxavir Marboxil in MENA

Fineline Cube Aug 21, 2025

On August 21, 2025, Nanjing Zenshine Pharmaceuticals Co., Ltd, a China-based developer of small molecule...

Policy / Regulatory

China Releases Draft Guidelines for Single-Arm Oncology Trials to Support Drug Approvals

Fineline Cube Aug 21, 2025

On August 20, 2025, the Center for Drug Evaluation (CDE) of the National Medical Products...

Company

Ascentage Pharma Reports H1 2025 Financial Results, Shows Strong Growth in Olverembatinib Sales

Fineline Cube Aug 21, 2025

China-based Ascentage Pharma (NASDAQ: AAPG; HKG: 6855) reported its financial results for the first half...

Company Drug

Chongqing Genrix Bio Pharmaceutical’s GR1802 Injection Receives NMPA Approval for Seasonal Allergic Rhinitis in Adolescents

Fineline Cube Aug 20, 2025

China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that its investigational product, GR1802...

Company Deals

Santhera Pharmaceuticals Signs Exclusive Agreement with Uniphar for AGAMREE Distribution in Middle East

Fineline Cube Aug 20, 2025

Swiss firm Santhera Pharmaceuticals (SWX: SANN), a leader in innovative therapies for rare diseases, has...

Company Deals

Vivatides Therapeutics Completes Multi-Million Dollar Seed Financing to Advance Nucleic Acid Delivery Platform

Fineline Cube Aug 20, 2025

Biopharmaceutical company Vivatides Therapeutics has successfully completed a multi-million dollar seed round financing led by...

Policy / Regulatory

China Unveils Ten Measures to Boost Family Doctor Contract Services

Fineline Cube Aug 20, 2025

In a significant move to enhance the quality and accessibility of primary healthcare, the National...

Company Deals

Hunan FangSheng Pharmaceutical to Acquire JAK Inhibitor Patent Rights for RMB 80 Million

Fineline Cube Aug 20, 2025

Hunan FangSheng Pharmaceutical Co., Ltd. (SHA: 603998) announced today that it has reached an agreement...

Company Drug

Haihe Biopharma Seeks Japan Approval for Risovalisib in PIK3CA-Mutated Ovarian Cancer

Fineline Cube Aug 20, 2025

Haihe Biopharma Co., Ltd. has filed a market application with Japan’s Ministry of Health, Labour...

Company Deals

XtalPi Collaborates with Dong-A ST on AI-Driven Drug Discovery for Immunological Diseases

Fineline Cube Aug 20, 2025

Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) and Korea’s leading pharmaceutical company, Dong-A...

Company Drug

Sino Biopharm’s LM-302 Shows Promising Results in Phase III Trials for Gastric Cancer

Fineline Cube Aug 20, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that LM-302, an innovative antibody-drug conjugate (ADC) developed...

Company Deals

GoodRx and Novo Nordisk Introduce $499 Monthly Pricing for Semaglutide Pens

Fineline Cube Aug 20, 2025

Goodrx Holdings Inc (NASDAQ: GDRX), the leading platform for medication savings in the U.S., has...

Company

InnoCare Pharma’s Orelabrutinib Powers 74.3% Revenue Surge in 2025 H1

Fineline Cube Aug 20, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) has unveiled its 2025 interim results, showcasing a...

Posts pagination

1 … 165 166 167 … 719

Recent updates

  • Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone
  • Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
  • Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
  • Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404
  • NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.